Novartis successor Elanco is laying off half the workforce in Basel

In 2014, Novartis spun off several corporate divisions. The animal health division was taken over by the subsidiary of the US pharmaceutical company Eli Lilly, Elanco.

Around 350 employees are distributed across the two Swiss locations of Basel and Saint-Aubin in the canton of Friborg. This number will now be reduced by 94 jobs, said a company spokeswoman “Switzerland up to date” With. The layoffs will take place in three phases from now until June 2021.

The reason for the downsizing is the purchase of Bayer’s animal health division in August. They now want to eliminate any duplication. Of the 3000 employees worldwide, 900 jobs would be cut, but in Basel it would hit an above-average number. However, the group failed to provide an explanation.

In Basel, research and development with 50 jobs, 27 jobs in production management and 17 in other functions are affected. Around 110 employees would remain in Basel after the dismantling.

Displeasure of the unions

Elanco’s restructuring plans do not necessarily meet with goodwill. Especially since the company made headlines with layoffs before (Telebasel reported). Earlier job cuts caused displeasure, as they followed promises to expand or secure locations.

As early as 2017, the Swiss Employees Union was angry because the layoffs were supposed to be very cautious. Even three years later, they want to forego media information. Only the information required by law was provided. The unions were not informed, explains SRF.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.